Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The National Institutes of Health awarded Joslin Diabetes Center $24.3 million to fund a clinical trial to study a potential treatment for kidney disease in people with type 1 diabetes. Alessandro Doria, M.D., Ph.D., M.P.H., an Investigator in the Section on Genetics and Epidemiology, Associate Professor of Medicine at Harvard Medical School and Associate Professor in the Department of Epidemiology at the Harvard School of Public Health, will lead the trial together with his co- Principal Investigator, Michael Mauer, M.D., Professor of Pediatrics and Medicine at the University of Minnesota Medical School.
The five-year trial will evaluate the possible benefits of allopurinol, an FDA approved uric acid lowering drug, in reducing kidney function loss among people with type 1 diabetes. The study stems from findings from Joslin and other investigators linking higher levels of serum uric acid to the risk of kidney complications in diabetes.
http://www.news-medical.net/news/20...r-kidney-disease-in-people-with-diabetes.aspx
The five-year trial will evaluate the possible benefits of allopurinol, an FDA approved uric acid lowering drug, in reducing kidney function loss among people with type 1 diabetes. The study stems from findings from Joslin and other investigators linking higher levels of serum uric acid to the risk of kidney complications in diabetes.
http://www.news-medical.net/news/20...r-kidney-disease-in-people-with-diabetes.aspx